A phase 2, randomized, multicenter study of adjuvant adebrelimab plus capecitabine in resected cholangiocarcinoma with high-risk factors: ACHIEVE.

Authors: Xiangcheng Li, Changxian Li, Yuan Cheng, Bin Zhang, Yonghua Xu

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps4220

Source: Full article

Abstract

TPS4220